How should herpes zoster be managed in adults, including antiviral therapy and pain control, with considerations for age and immunocompromised status?

Herpes Zoster Management

Start oral antiviral therapy (acyclovir, valacyclovir, or famciclovir) within 72 hours of rash onset for all adults, but use high-dose IV acyclovir for immunocompromised patients, and combine with aggressive pain management using the WHO pain ladder plus anticonvulsants to prevent postherpetic neuralgia.

Antiviral Therapy Algorithm

For Immunocompetent Adults

• Initiate treatment within 72 hours of rash appearance 12
• Oral options (all equally effective):
  • Acyclovir 800 mg 5 times daily
  • Valacyclovir (preferred for convenience)
  • Famciclovir
• Continue for 7-10 days as lesions crust over 1

For Immunocompromised Patients

• High-dose IV acyclovir is the treatment of choice 3
• This includes patients with:
  • Active chemotherapy
  • Hematopoietic stem cell or solid organ transplant recipients
  • HIV/AIDS
  • Chronic immunosuppressive medications
• Critical caveat: Immunocompromised patients have 25-45% risk of developing dermatomal zoster with 10-20% risk of dissemination without prompt IV therapy 3
• Lesions continue erupting for 7-14 days (versus 4-6 days in healthy hosts) and heal more slowly 3
• Oral therapy may be used only for mild cases or to complete therapy after clinical response to IV treatment 3

Special Situations Requiring IV Therapy

• HZ ophthalmicus (eye involvement)
• HZ oticus (ear involvement)
• Neurological complications
• Disseminated disease
• These require interdisciplinary management 4

Pain Management Strategy

Acute Phase (During Active Rash)

Early and aggressive pain control is essential to reduce postherpetic neuralgia (PHN) risk 4

1. WHO pain ladder approach:

   • Mild pain: NSAIDs/acetaminophen
   • Moderate pain: Add weak opioids
   • Severe pain: Strong opioids

2. Add anticonvulsant adjuvants early 4:

   • Gabapentin
   • Pregabalin

Postherpetic Neuralgia (Pain >90 days)

PHN occurs in approximately 20% of patients (1 in 5) 1

Treatment hierarchy 1:

• First-line: Gabapentin or pregabalin
• Second-line: Tricyclic antidepressants
• Topical options: Lidocaine patches or capsaicin cream

Age-Specific Considerations

Older Adults (≥60 years)

• Higher risk for both HZ and PHN 5
• PHN can be debilitating in elderly patients 5
• More aggressive early treatment warranted
• Longer pain management strategy often required 5

Younger Adults

• HZ is rare unless immunocompromised or metabolic/neoplastic disorders present 6
• Standard oral antiviral therapy usually sufficient

Critical Pitfalls to Avoid

1. Antiviral resistance: If lesions develop in patients already taking prophylactic acyclovir (800 mg bid) or valacyclovir (500 mg bid), suspect resistance and adjust empiric therapy 3

2. Delayed treatment: The 72-hour window is critical—treatment beyond this timeframe has diminished efficacy 12

3. Inadequate pain control: Undertreating acute pain increases PHN risk; be aggressive early 4

4. Wrong route in immunocompromised: Oral antivirals are insufficient for severely immunosuppressed patients—use IV acyclovir 3

5. Chronic ulcerations: Without adequate treatment, immunocompromised patients develop persistent viral replication complicated by secondary bacterial and fungal superinfections 3

Vaccination for Prevention

• Recombinant zoster vaccine (Shingrix) recommended for adults ≥60 years 4
• For immunocompromised patients ≥50 years 4
• Significantly reduces both HZ incidence and PHN 2